Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market\Roots

narender.shukla@rootsanalysis.co

177
views

Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market

The approval ofKYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest ofpharma stakeholders in cell therapies; further, owing to the technicalchallenges in this field, outsourcing manufacturing operations has become anecessity

Roots Analysis has announced theaddition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list ofofferings.

Owingto various reasons, the demand for cell therapies is anticipated to increase overthe coming years. Therefore, both therapy developers and contract serviceproviders may need to strengthen their capabilities and expand availablecapacity. In this context, automation is expected to be a key enabler withinthe cell therapy manufacturing and contract services industry.

To order this 550+ page report, which features160+ figures and 250+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

KeyMarket Insights

Morethan 160 organizations claim to be engaged in cell therapy manufacturing

Themarket landscape is dominated by industry players, representing more than 60%of the total number of stakeholders. Amongst these, over 55 are large ormid-sized firms (having more than 50 employees).

100+ players focused on T-cell and stem cell therapies

Mostof these players are focused on manufacturing T-cell therapies, including CART,TCR or TILs. It is worth highlighting that more than 35 organizations claim tohave necessary capabilities for the manufacturing of both types of therapies.

Presently, 70+ companies have commercial scale capacity

Asmajority of the cell therapy products are in clinical trials, the demand ishigh at this scale. However, it is worth noting that several players (~50%)have already developed commercial scale capacity for cell therapies.

Europe is currently considered a current hub for celltherapy production

Morethan 220 manufacturing facilities have been established by various players,worldwide; of these, 35% are in Europe, followed by those based in NorthAmerica. Other emerging regions include Australia, China, Japan, Singapore,South Korea and Israel.

50+ facility expansions reported between 2015-2019

Morethan 85% of the expansions are related to setting up of new facilities acrossdifferent regions. Maximum expansion activity was observed in the US and incertain countries within the Asia Pacific regions.

20+companies offer automated solutions to cell therapy developers

Playersthat claim to offer consultancy services related to automation include (inalphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix,FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identifiedplayers, namely (in alphabetical order) Fraunhofer Institute forManufacturing Engineering and Automation IPA, Invetech, KMC Systems, MayoClinic Center for Regenerative Medicine and RoosterBio, that offer consultancysolutions related to automation.

Partnershipactivity has grown at an annualized rate of 16%, between 2014 and 2018

Morethan 200 agreements have been inked in the last 5 years; majority of these werefocused on the supply of cell-based therapy products for clinical trials. Otherpopular types of collaboration models include manufacturing process developmentagreements (16%), services agreements (12%) and acquisitions (10%).

By2030, developed geographies will capture over 60% of the market share

AsiaPacific is anticipated to capture the major share (~36%) of the market by 2030.It is also important to highlight that financial resources, technical expertiseand established infrastructure is likely to drive cell therapy manufacturingmarket in Europe, which is estimated to grow at a CAGR of ~26%.

To request a samplecopy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/285/request-sample.html

Key Questions Answered

§ What is the globaldemand for cell-based therapies?

§ Who are the keymanufacturers (industry / non-industry) of cell-based therapies, across theworld?

§ What are the majorrecent developments (such as partnerships and expansions) in this industry?

§ What kind ofpartnership models are commonly adopted by stakeholders in this domain?

§ What is the current, installedcontract manufacturing capacity for cell therapies?

§ What are the keyfactors influencing the make (manufacture in-house) versus buy(outsource) decision related to cell therapies?

§ What are the keyparameters governing the cost of cell therapy manufacturing?

§ What are important technologyplatforms (available / under development) for cell therapy development andmanufacturing?

§ Whatare the key drivers and growth constraints in cell therapy manufacturing market?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?

The USD 11 billion (by 2030) financial opportunitywithin the cell therapy manufacturing market has been analyzed across thefollowing segments:

§ Type of therapy

§ T-cell therapies(CAR-T therapies, TCR therapies, TIL therapies)

§ Dendritic celltherapies

§ Tumor cell therapies

§ NK cell therapies

§ Stem cell therapies

§ Source of cells

§ Autologous

§ Allogeneic

§ Scale of operation

§ Clinical

§ Commercial

§ Purpose ofmanufacturing

§ Contractmanufacturing

§ In-housemanufacturing

§ Key geographicalregions

§ North America

§ Europe

§ Asia Pacific

§ Rest of the world

Thereport features inputs from eminent industry stakeholders, according to whom themanufacturing of cell therapies is largely being outsourced due to exorbitantcosts associated with the setting-up of in-house expertise. The report includesdetailed transcripts of discussions held with the following experts:

§ Victor Lietao Li (Co-Founderand Chief Executive Officer, Lion TCR)

§ Tim Oldham (ChiefExecutive Officer, Cell Therapies)

§ Gerard MJ Bos (ChiefExecutive Officer, CiMaas)

§ Wei (William) Cao (ChiefExecutive Officer, Gracell Biotechnologies)

§ Troels Jordansen (ChiefExecutive Officer, Glycostem Therapeutics)

§ Arik Hasson (ExecutiveVP Research and Development, Kadimastem)

§ Gilles Devillers (GeneralManager, Bio Elpida)

§ Arnaud Deladeriere (Manager,Business Development & Operations-cGMP Manufacturing Unit, Center ofExcellence for Cellular Therapy / C3i)

§ Brian Dattilo (Managerof Business Development, Waisman Biomanufacturing)

§ Fiona Bellot (BusinessDevelopment Manager, RoslinCT)

§ Mathilde Girard (DepartmentLeader, Cell Therapy Innovation and Development, YposKesi)

§ David Mckenna (Professorand American Red Cross Chair in Transfusion Medicine, University of Minnesota)

Theresearch covers profiles of key players (industry and non-industry) that offermanufacturing services for cell-based therapies, featuring a company overview, informationon manufacturing facilities, and recent collaborations.

§ BioNTech InnovativeManufacturing Services

§ Cell Therapies

§ Cell and Gene TherapyCatapult

§ Center for Cell andGene Therapy, Baylor College of Medicine

§ Centre for Cell ManufacturingIreland, National University of Ireland

§ Clinical Cell andVaccine Production Facility, University of Pennsylvania

§ Cognate BioServices

§ FUJIFILM

§ Guy’s and St. Thomas’GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Celland Gene Medicine, Stanford University